BACKGROUND: @entity1088 is the drug of choice for @entity1 with unsatisfactory response to routine antipsychotic treatment. Polypharmacy is widely used among @entity1 having @entity1088 -resistant @entity161 , although no solid evidence exists for any effective augmentation therapy for this @entity1 population. We aimed to study the efficacy of @entity2812 in the treatment of @entity1088 -resistant @entity161 . METHOD: We conducted electronic searches of the Cochrane PsiTri database, the Website of metaRegister of Controlled Trials, including NIH ClinicalTrials.gov, and a clinical trial register by the manufacturer of @entity2812 (GlaxoSmithKline). All randomized placebo-controlled studies on @entity1 receiving @entity1088 were included in the analysis. The primary outcome measure was a total score for symptoms of @entity716 , and the secondary outcome measures were scores for positive and negative symptoms of @entity716 . For continuous and binary data, standardized mean differences (SMD), and odds ratios (OR) and the number needed to treat (NNT) were calculated, respectively. RESULTS: Five trials with 10 to 24 weeks duration and total of 161 randomized @entity1088 @entity1 were included in the meta-analysis. @entity2812 was superior to placebo augmentation in both the primary outcome measure (SMD 0.57, 95%CI 0.25-0.89, p<0.001; OR 0.19, 95%CI 0.09-0.43, p<0.001; NNT 4, 95%CI 3-6) and secondary outcome measures (SMD 0.34, 95%CI 0.02-0.65 for positive symptoms, SMD 0.43, 95%CI 0.11-0.75 for negative symptoms). CONCLUSIONS: This meta-analysis suggests that @entity2812 augmentation may be an effective treatment for @entity1 with @entity1088 -resistant @entity161 . A substantial proportion of these most severely ill @entity1 appeared to obtain clinically meaningful benefit from this combination treatment.

The efficacy of @entity2812 in @entity1088 -resistant XXXX : a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['Clozapine', 'clozapine'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis'] @entity2812 :: ('MESH:C047781', 'Chemical') :: ['lamotrigine', 'Lamotrigine']
@entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']
